Journal of Clinical Endocrinology & Metabolism, Vol 70, 453-460, Copyright © 1990 by Endocrine Society

ARTICLES

Applications of a new chemiluminometric thyrotropin assay to subnormal measurement

CA Spencer, JS LoPresti, A Patel, RB Guttler, A Eigen, D Shen, D Gray and JT Nicoloff
Department of Medicine, University of Southern California School of Medicine, Los Angeles 90033.

A new immunochemiluminometric TSH assay (ICMA) was shown to offer improved analytical (+2 SD of zero) and functional (20% interassay coefficient of variation) sensitivity [0.003 vs 0.045 +/- 0.005 (+/- SE; range, 0.01-0.07); 0.018 vs. 0.23 +/- 0.02 (range, 0.10-0.35, mU/L); analytical vs. functional sensitivity limit for the ICMA vs. 10 other TSH immunometric assays, respectively]. The ICMA was used to study the physiological relationship between serum TSH and free T4 [as reflected by free T4 index (FT4I)] values at both steady state and 14 days after acute pharmacological T4 administration (3 mg oral T4 load plus 0.3 mg daily). At steady state, an inverse log/linear relationship was found between serum TSH and FT4I values (log TSH = 2.56 - 0.022 FT4I; r = 0.84; P less than 0.001). Ten to 14 days after acute T4 suppression in 5 euthyroid subjects, serum TSH/FT4I levels had plateaued after decreasing in parallel to the slope of the steady state relationship, suggesting that the degree of T4 suppression of TSH can be predicted from an individual's pituitary TSH/free T4 set-point and the magnitude of the serum T4 elevation achieved. Ambulatory and hospitalized patient sera, previously identified as having low (less than 0.1 mU/L) TSH levels by a less sensitive assay, were restudied by the TSH ICMA. Normal TSH values ranged from 0.39-4.6 mU/L, whereas the majority of hyperthyroid patients [52 of 54 (96% ambulatory) and 22 of 23 (96%, hospitalized)] had undetectable (less than 0.005 mU/L), basal TSH levels and absent TRH stimulated TSH responses. In contrast, most (32 of 37; 86%) of hospitalized nonhyperthyroid patients with low (less than 0.1 mU/L) TSH values due to nonthyroidal illness or glucocorticoid treatment had detectable (greater than 0.01 mU/L) basal and TRH stimulated TSH levels. The positive relationship between basal and TRH- stimulated TSH levels was shown to extend down to the detectability limit of the assay (0.005 mU/L), which further supported the authenticity of the subnormal TSH ICMA measurements. The new TSH ICMA is considered to represent the first of a third generation of clinical TSH assays, since it has a functional (interassay) sensitivity that is 2 orders of magnitude greater than that of typical first generation TSH RIAs and 1 order of magnitude greater than current second generation TSH immunometric methods. Such third generation TSH assays will facilitate both the optimization of T4 therapy as well as the diagnosis of hyperthyroidism in hospitalized patients with nonthyroidal illness.

This article has been cited by other articles:

				P. A. Boepple, F. J. Hayes, A. A. Dwyer, T. Raivio, H. Lee, W. F. Crowley Jr, and N. Pitteloud Relative Roles of Inhibin B and Sex Steroids in the Negative Feedback Regulation of Follicle-Stimulating Hormone in Men across the Full Spectrum of Seminiferous Epithelium Function J. Clin. Endocrinol. Metab., May 1, 2008; 93(5): 1809 - 1814. [Abstract] [Full Text] [PDF]

				S. Wilson, J. V. Parle, L. M. Roberts, A. K. Roalfe, F. D. R. Hobbs, P. Clark, M. C. Sheppard, M. D. Gammage, H. M. Pattison, J. A. Franklyn, et al. Prevalence of Subclinical Thyroid Dysfunction and Its Relation to Socioeconomic Deprivation in the Elderly: A Community-Based Cross-Sectional Survey J. Clin. Endocrinol. Metab., December 1, 2006; 91(12): 4809 - 4816. [Abstract] [Full Text] [PDF]

				M. Boas, U. Feldt-Rasmussen, N. E Skakkebaek, and K. M Main Environmental chemicals and thyroid function. Eur. J. Endocrinol., May 1, 2006; 154(5): 599 - 611. [Abstract] [Full Text] [PDF]

				K Boelaert and J A Franklyn Thyroid hormone in health and disease J. Endocrinol., October 1, 2005; 187(1): 1 - 15. [Abstract] [Full Text] [PDF]

				B. Biondi, E. A. Palmieri, M. Klain, M. Schlumberger, S. Filetti, and G. Lombardi Subclinical hyperthyroidism: clinical features and treatment options Eur. J. Endocrinol., January 1, 2005; 152(1): 1 - 9. [Abstract] [Full Text] [PDF]

				P. W. Clyde, A. E. Harari, E. J. Getka, and K. M. M. Shakir Combined Levothyroxine Plus Liothyronine Compared With Levothyroxine Alone in Primary Hypothyroidism: A Randomized Controlled Trial JAMA, December 10, 2003; 290(22): 2952 - 2958. [Abstract] [Full Text] [PDF]

				J. A. Sgarbi, F. G. Villaca, B. Garbeline, H. E. Villar, and J. H. Romaldini The Effects of Early Antithyroid Therapy for Endogenous Subclinical Hyperthyroidism in Clinical and Heart Abnormalities J. Clin. Endocrinol. Metab., April 1, 2003; 88(4): 1672 - 1677. [Abstract] [Full Text] [PDF]

				S. R. Rose Individual Set Points for Thyroid Function Tests AAP Grand Rounds, July 1, 2002; 8(1): 5 - 6. [Full Text] [PDF]

				A. Alkhateeb, G. L. Stetler, W. Old, J. Talbert, C. Uhlhorn, M. Taylor, A. Fox, C. Miller, D. G. Dills, E. C. Ridgway, et al. Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2 Hum. Mol. Genet., March 1, 2002; 11(6): 661 - 667. [Abstract] [Full Text] [PDF]

				S. Andersen, K. M. Pedersen, N. H. Bruun, and P. Laurberg Narrow Individual Variations in Serum T4 and T3 in Normal Subjects: A Clue to the Understanding of Subclinical Thyroid Disease J. Clin. Endocrinol. Metab., March 1, 2002; 87(3): 1068 - 1072. [Abstract] [Full Text] [PDF]

				A C Al-Abadi Subclinical thyrotoxicosis Postgrad. Med. J., January 1, 2001; 77(903): 29 - 29. [Full Text]

				S. Ercan-Fang, H. L. Schwartz, C. N. Mariash, and J. H. Oppenheimer Quantitative Assessment of Pituitary Resistance to Thyroid Hormone from Plots of the Logarithm of Thyrotropin Versus Serum Free Thyroxine Index J. Clin. Endocrinol. Metab., June 1, 2000; 85(6): 2299 - 2303. [Abstract] [Full Text]

				G. J. Canaris, N. R. Manowitz, G. Mayor, and E. C. Ridgway The Colorado Thyroid Disease Prevalence Study Arch Intern Med, February 28, 2000; 160(4): 526 - 534. [Abstract] [Full Text] [PDF]

				D. C Bauer Review: sensitive thyrotropin testing in unselected inpatients has low diagnostic accuracy Evid. Based Med., January 1, 2000; 5(1): 29 - 29. [Full Text] [PDF]

				Levothyroxine Suppression of Thyroglobulin in Patients with Differentiated Thyroid Carcinoma J. Clin. Endocrinol. Metab., December 1, 1999; 84(12): 4549 - 4553. [Abstract] [Full Text]

				M. M. Kaplan Clinical Perspectives in the Diagnosis of Thyroid Disease Clin. Chem., August 1, 1999; 45(8): 1377 - 1383. [Abstract] [Full Text] [PDF]

				J. Attia, P. Margetts, and G. Guyatt Diagnosis of Thyroid Disease in Hospitalized Patients: A Systematic Review Arch Intern Med, April 12, 1999; 159(7): 658 - 665. [Abstract] [Full Text] [PDF]

				E. Fliers, S. E. F. Guldenaar, W. M. Wiersinga, and D. F. Swaab Decreased Hypothalamic Thyrotropin-Releasing Hormone Gene Expression in Patients with Nonthyroidal Illness J. Clin. Endocrinol. Metab., December 1, 1997; 82(12): 4032 - 4036. [Abstract] [Full Text] [PDF]

				P. Sotorrio, A. Quiros, and J. M. Izquierdo New Immunoelectrochemiluminometric Assay to Measure Serum Thyrotropin, Clin. Chem., December 1, 1997; 43(12): 2428 - 2430. [Full Text]

				R. Sapin, F. Gasser, M. d'Herbomez, J. L. Wemeau, C. Ebert, and J. L. Schlienger Elecsys(R) Thyrotropin (TSH) Assay Evaluated Clin. Chem., March 1, 1997; 43(3): 545 - 547. [Full Text]

				M. Ito, J. Takamatsu, S. Yoshida, Y. Murakami, S. Sakane, K. Kuma, and N. Ohsawa Incomplete Thyrotroph Suppression Determined by Third Generation Thyrotropin Assay in Subacute Thyroiditis Compared to Silent Thyroiditis or Hyperthyroid Graves' Disease J. Clin. Endocrinol. Metab., February 1, 1997; 82(2): 616 - 619. [Abstract] [Full Text] [PDF]

				A. D. Toft Thyroxine Therapy N. Engl. J. Med., July 21, 1994; 331(3): 174 - 180. [Full Text]